RxDoctor Payments DataLook up a doctor →

Pavan Ahuja, MD

Internal Medicine · Elkhart, INNPI 1578566675

Payments from drug & device makers

$26,202in general payments, 2019–2025

Across 1,451 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Lilly USA, LLC$2K
  • Amgen$2K
  • Novo Nordisk$2K
  • GSK$2K
  • AbbVie$2K
  • plus $14K from 51 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)94$2,599
Lilly USA, LLC140$2,459
Amgen76$1,985
Novo Nordisk130$1,833
GSK117$1,596
AbbVie(2 entities)88$1,587
Esperion Therapeutics, Inc.46$1,565
Insulet Corporation86$1,342
Merck109$1,302
Bayer43$1,117
Abbott57$1,085
Boehringer Ingelheim53$842
Pfizer69$784
Xeris Pharmaceuticals, Inc.32$489
Johnson & Johnson(2 entities)39$473
Novartis32$373
Mylan Specialty L.p.17$345
Sumitomo Pharma America, Inc.20$325
Astellas Pharma US Inc10$298
Dexcom, Inc.20$298
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$248
Sunovion Pharmaceuticals Inc.21$240
Amneal Pharmaceuticals LLC14$218
Viatris Specialty LLC9$200
Amarin Pharma, Inc.13$182
Idorsia Pharmaceuticals US Inc5$167
Biohaven Pharmaceutical Holding Company Ltd.2$162
IBSA Pharma Inc.11$159
Lundbeck LLC3$159
Radius Health, Inc.9$158
Sanofi-aventis U.S. LLC9$149
Otsuka America Pharmaceutical, Inc.7$136
Cequr Corporation2$128
Biohaven Pharmaceuticals, Inc.6$118
BETA Bionics, Inc.1$114
Tandem Diabetes Care, Inc.2$109
Recordati_rare_diseases_inc.3$73
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$71
Antares Pharma, Inc.4$63
Exact Sciences4$60
Medtronic(2 entities)3$56
Shire North American Group Inc3$55
Grifols USA, LLC3$54
Eisai Inc.3$51
Neurocrine Biosciences, Inc.2$48
Vanda Pharmaceuticals Inc.1$37
Lifescan, Inc.2$37
Nevro Corp.2$35
Kowa Pharmaceuticals America, Inc.3$34
Zyla Life Sciences, Inc.2$32
Amryt Pharma Holdings Ltd2$28
Ultragenyx Pharmaceutical Inc.1$26
Biocryst US Sales Co., LLC1$24
Boston Scientific1$21
Phathom Pharmaceuticals, Inc.1$20
Optos, Inc.1$20
Puma Biotechnology, Inc.1$18

How this compares

$26,202 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana →

Medicare billing

Part B allowed, 2024
$622,241
Medicare patients
335
Services billed
40,107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Elkhart

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →